Tuesday

24th May 2022

Drug supplies to EU crisis countries at risk, warn health analysts

  • Drug speculation threatens supplies, says GlobalData (Photo: Derek K. Miller)

Speculators are threatening the supply of medication to countries worst hit by the sovereign debt crisis, according to research by business analysts GlobalData.

GlobalData's report, published Wednesday (22 August) claimed that pharmacies in Greece and other South Mediterranean countries had cut drug prices in a bid to enable people to pay for their medicines.

Read and decide

Join EUobserver today

Become an expert on Europe

Get instant access to all articles — and 20 years of archives. 14-day free trial.

... or subscribe as a group

But theprice-cuts had led to speculators and wholesalers buying up medicines at knock-down prices in one member state and selling them in another.

GlobalData analyst Michael Leibfried, who asserted that drug companies in Europe were facing "renewed pricing pressure from all directions", described the practice as a "lucrative export carry trade" that was "shrinking prices in other countries due to reference pricing." The practice also threatens the supply of medicines to the EU's crisis-hit countries.

Although OECD figures suggest that European governments are still allocating 8-12% of public spending to healthcare, austerity budgets have already seen attempts by governments to cut back on drug bills, even in more prosperous countries.

Following the lead of the UK's National Institute for Clinical Excellence (Nice), which controls drug purchases for the NHS, the German government last year adopted legislation requiring drug companies to prove the price benefits of new medicines, in a move aimed at tightening costs for new medicines.

Under EU law national governments are solely responsible for negotiating drug prices with companies. However, GSK boss Andrew Witty, who also leads the European Federation of Pharmaceutical Industries and Associations (EFPIA), wants EU countries to agree to exclude bail-out countries from price referencing.

Last month the lobby group asked the EU commission to impose a temporary ban on drug re-exports, although this would breach internal market rules on the free movement of goods and services.

The EFPIA insists that drug companies made discounts and price-cuts worth €7 billion in 2010 and 2011 in the five countries Greece, Ireland, Italy, Portugal and Spain, accounting for 8 percent of the industry's turnover. They were also risking further multi-billion euro losses by making emergency plans to supply drugs to Greece, and other countries, in the event of them being forced out of the eurozone, Witty said.

Pharmaceutical giants are concerned that lower drug prices in crisis-hit countries are being used for benchmark pricing of drugs. Most member states base their medicine purchase prices on average prices across the EU.

Critics claim that the reference pricing scheme prevents companies charging over the odds for new drugs.

Meanwhile, drug giants also have fears about whether governments can pay their bills. In July, Swiss company Roche claimed that the five crisis euro countries owed €1.2 billion to settle unpaid drug bills. Figures collected by pharmaceuticals indicated that only 1 percent of drug sales to the Greek government had been paid for in the first three months of 2012.

IMF worried by social cost of Greek austerity

The Greek economy and its people are reaching the "limit" of what they can endure in terms of austerity cuts, a senior IMF official has said in unusually political remarks.

EU drugs regulator accused of being too cozy with Big Pharma

The European Parliament has refused to sign off on the accounts of the EU agency responsible for making sure all medicines in Europe are safe and effective for its citizens to use, accusing the body of being too close to Big Pharma.

Opinion

Georgia, Moldova, Ukraine - the case for granting EU candidacy

Granting EU candidacy status to Georgia, Moldova and Ukraine will firmly anchor their ties with Brussels — and enable the EU to secure its place in the Black Sea region, connecting Europe to China and energy-rich Central Asia, bypassing Russia.

Opinion

The EU Parliament Covid inquiry: the questions MEPs must ask

A basic lack of transparency around the EU's vaccines procurement negotiations has prevented effective public and parliamentary scrutiny. It has also made it impossible to answer some of the key questions we put forward here.

News in Brief

  1. France 'convinced' Ukraine will join EU
  2. Von der Leyen: Russia hoarding food as 'blackmail'
  3. Legal action launched against KLM over 'greenwashing'
  4. Orbán refuses to discuss Russia oil embargo at EU summit
  5. Turkey's Erdogan snubs Greek PM
  6. ECB: Crypto may pose a risk to financial stability
  7. UK PM Johnson faces renewed questions over Covid party
  8. Sweden gives 5th Covid shot to people over 65, pregnant women

Stakeholders' Highlights

  1. Nordic Council of MinistersNordic delegation visits Nordic Bridges in Canada
  2. Nordic Council of MinistersClear to proceed - green shipping corridors in the Nordic Region
  3. Nordic Council of MinistersNordic ministers agree on international climate commitments
  4. UNESDA - SOFT DRINKS EUROPEEfficient waste collection schemes, closed-loop recycling and access to recycled content are crucial to transition to a circular economy in Europe
  5. UiPathNo digital future for the EU without Intelligent Automation? Online briefing Link

Latest News

  1. Orbán oil veto to deface EU summit on Ukraine
  2. France aims for EU minimum-tax deal in June
  3. 'No progress in years' in Libya, says UN migration body
  4. Toxic pesticide residue in EU fruit up 53% in a decade
  5. Orbán's overtures to Moscow are distasteful and detrimental
  6. The Polish-Lithuanian Commonwealth is back
  7. EU aims to seize Russian assets amid legal unclarity
  8. Close ties with autocrats means security risk, Nato chief warns

Join EUobserver

Support quality EU news

Join us